WJ22096

Nanjing Jingao biomidical technology Co. Ltd. · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	WJ22096
Sponsor	Nanjing Jingao biomidical technology Co. Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

WJ22096 CI brief — competitive landscape report
WJ22096 updates RSS · CI watch RSS
Nanjing Jingao biomidical technology Co. Ltd. portfolio CI